Safety, Efficacy, and Effectiveness of Delabeling in Patients with Multiple Drug Allergy Labels

Abstract

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Low-risk penicillin allergy delabeling through a direct oral challenge in immunocompromised and/or multiple drug allergy labeled patients in a critical care setting

“…4 The most commonly listed drug labels in those with MDAL include beta-lactam antibiotics and sulfonamide antibiotics. 5 Therefore, it is expected that critically ill, immunocompromised patients with MDAL will disproportionately benefit from access to penicillin as a potential antibiotic therapy.…”

Allergic Reactions After COVID-19 Vaccination—Putting Risk Into Perspective

“…The exclusion of those with reactions to 2 or more non-PEG-containing injectable drugs from vaccination with the Pfizer-BioNTech SARS-CoV-2 mRNA vaccine is a practice that would not be currently recommended. 3 In addition, this study also did not measure levels of serum tryptase, a marker of anaphylaxis, and therefore gives us no direct insight into mechanisms. Nonetheless, this work by Shavit et al 1 provides a pragmatic strategy and underscores the enormous success of the vaccine rollout in Israel.…”

Standards for practical intravenous rapid drug desensitization & delabeling: A WAO committee statement

“…199 Currently, it is estimated that sulfa antibiotics are the most common antibiotic label following penicillin. 200 The approach to sulfonamide DHRs might vary depending on the type of reaction and the risk assessment; however, the usefulness of skin testing seems to be limited to specific cases and DPT seems to be the main delabeling tool. 198 Previous guidelines supported multidose DPT approaches to sulfa antibiotics.…”